To the Editor: In the article by the RTS, S Clinical Trials Partnership (Nov. 17 issue) 1 on the
phase 3 trial of RTS, S (ClinicalTrials. gov number, NCT00866619), an analysis of the …

Methods In this phase III double-blind trial, 6537 infants (aged 6–12 weeks) and 8922
children (aged 5–17 months) were enrolled at 11 centres in seven countries, from 2009 to …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …